Independent clinical features/risk factors associated with the use of vasoactive drugs (multivariable logistic regression). Values are OR (95% CI).
| Characteristics | PDE5 Inhibitors | ET1RA | ACE Inhibitors and/or AT1RA | IV Prostanoids |
|---|---|---|---|---|
| Female | — | — | 0.6 (0.5–0.7), p < 0.001 | — |
| Age, yrs | — | — | 1.007 (1.002–1.011), p = 0.006 | — |
| RP | — | — | — | 5.1 (1.2–21.4), p = 0.026 |
| PAH | 7.2 (4.5–11.7), p < 0.001 | 6.9 (4.8–9.8), p < 0.001 | 1.8 (1.5–2.3), p < 0.001 | — |
| DU | 1.5 (0.9–2.4), p = 0.095 | 2.8 (2.0–3.9), p < 0.001 | — | 1.7 (1.4–2.2), p < 0.001 |
| HTN | — | — | 5.4 (4.5–6.5), p < 0.001 | 0.7 (0.5–0.9), p = 0.005 |
PDE5: phosphodiesterase type 5; ET1RA: endothelin 1 receptor antagonists; ACE: angiotensin-converting enzyme; AT1RA: angiotensin 1 receptor antagonists; IV: intravenous; RP: Raynaud phenomenon; PAH: pulmonary arterial hypertension; DU: digital ulcers; HTN: hypertension.